SLXN

Silexion Therapeutics Corp
CAPPED RATING

Silexion Therapeutics Corp (SLXN) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F). The rating has held at C for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
F
Factor Score 0.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.1
EV / EBITDA 0.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -80.5%
Price Return 12M -99.7%
Catalyst Signal 0.00
Market Cap $1.3M
TTM Revenue N/A
Price / Sales N/A
ROE N/A

Historical Factor Score Progression

Held C for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B+ (3.7) D+ (1.8) C+ (2.8) F (0.3) C+ (2.6) C (2.3)
2026-11-07 A- (3.9) C- (1.9) C+ (2.8) F (0.3) C+ (2.7) C (2.3)
2026-10-31 B+ (3.7) D+ (1.8) C+ (2.8) F (0.3) C+ (2.7) C (2.3)
2026-10-24 C+ (2.5) C- (1.9) C+ (2.8) F (0.3) C+ (2.6) C- (2.0)
2026-10-17 C+ (2.5) D+ (1.8) C+ (2.8) F (0.3) C+ (2.6) C- (2.0)
Page 1 of 4